FPI(300203)2022-04-27 16:00Financial Performance - The company's operating revenue for the reporting period was 3.75 billion RMB, a decrease of 8.55% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -350 million RMB, a decline of 522.04% year-on-year[6]. - The gross profit decreased by 300 million RMB compared to the same period last year due to declining revenue and rising operating costs[6]. - The company's total revenue for 2021 was approximately 3.75 billion yuan, a decrease of 8.55% compared to 2020[115]. - The net profit attributable to shareholders was -350 million yuan, representing a decline of 522.04% year-on-year[115]. - The main business revenue was 3.62 billion yuan, accounting for 96.65% of total revenue, with a year-on-year decrease of 9.24%[116]. - The revenue from instruments and related software and consumables was 2.09 billion yuan, which is 55.63% of total revenue, down 18.24% from the previous year[116]. - Domestic revenue was approximately 3.70 billion yuan, representing 98.63% of total revenue, with a decrease of 9.00% year-on-year[116]. - The company achieved a sales volume of 29,577 units in 2021, an increase of 12.85% compared to 2020[120]. Research and Development - The company increased its R&D investment by 72.38 million RMB compared to the previous year to maintain continuous innovation and technological leadership[6]. - The company has invested a total of 2.5 billion yuan in R&D, developing nearly 100 technology platforms across various fields, including spectroscopy, chromatography, and mass spectrometry[112]. - The total R&D investment amounted to ¥523,274,938.02, representing 13.95% of operating revenue, up from 11.20% the previous year[141]. - The number of R&D personnel increased by 25.06% to 1,487 from 1,189, with the proportion of R&D personnel rising to 22.38% from 19.63%[139]. - R&D expenses rose by 14.79% to ¥561,800,325.80 from ¥489,424,753.75, attributed to an increase in the total salary of R&D personnel[136]. Market and Business Strategy - The total amount of new contracts signed by the company was approximately 4.1 billion RMB, with a significant contribution of about 1.34 billion RMB from its subsidiary, which represents a growth of approximately 65% year-on-year[6]. - The company is focused on expanding its technology platforms and applications in various sectors, including semiconductor and environmental monitoring[43]. - The company aims to establish a comprehensive monitoring solution that integrates air quality, photochemical components, particulate matter, and toxic gases, contributing to the goal of building a beautiful China[49]. - The company is actively developing a range of online monitoring instruments for specific water quality factors, achieving laboratory-level analytical precision for low-concentration indicators in surface water[50]. - The company is expanding its market presence in the life sciences sector through the commercialization of new diagnostic systems and analytical instruments[136]. Risk Management - The company does not face major risks regarding its ongoing operations, and the industry does not exhibit overcapacity or continuous decline[6]. - The company is committed to addressing various risks, including technological, market, and operational risks, as detailed in the management discussion and analysis section[9]. - The company faces technology risks due to the rapid emergence of innovative companies and the need to continuously develop new products and technologies[165]. - The company is addressing operational risks related to environmental monitoring and data integrity, which could impact its reputation and operations[166]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring compliance with legal regulations[185]. - The company strictly adheres to information disclosure requirements, ensuring timely and fair access to information for all shareholders[181]. - The company has implemented a structured governance framework, including specialized committees to enhance decision-making capabilities[181]. - The company emphasizes compliance with laws and regulations, enhancing its compliance system in light of the issues identified in the Tangshan case[170]. Subsidiaries and Investments - The company established several new subsidiaries in 2021, including Hangzhou Shenghui Intelligent Technology Co., Ltd. with an investment of 3,500,000.00 CNY and a 65% ownership stake[128]. - The company disposed of 45% equity in Wuxi Zhongke, resulting in a loss of control with a fair value of 105,750,000.00 CNY and a gain of 53,789,449.75 CNY recognized[124]. - The company has established several business units, including Pujing Medical and Pukang Medical, focusing on clinical diagnostics and life sciences, leveraging advanced analytical technologies such as mass spectrometry and chromatography[99]. Environmental Commitment - The company is committed to supporting the national ecological civilization construction and pollution prevention efforts, enhancing environmental governance capabilities and promoting green high-quality development[57]. - The company is actively contributing to China's carbon peak and carbon neutrality goals, developing various carbon monitoring technologies and solutions to support greenhouse gas management[62]. - The company has created a comprehensive carbon monitoring solution that includes fixed pollution source monitoring, mobile monitoring, and satellite remote sensing, forming a three-dimensional network for urban greenhouse gas concentration monitoring[63].